Research indicates that breast cancer exhibits considerable heterogeneity, with distinct molecular subtypes, such as luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC), each having different biological behaviours and responses to treatment.3,10 This heterogeneity poses challenges in developing effective treatment strategies tailored to individual patients. The gene discussed is ERBB2; the disease is breast cancer.